Technology Offerings

Alzheimer's Disease therapy with antibody against oligomeric Abeta peptides

A novel, proprietary antibody for the therapy and/or diagnosis of Alzheimer's Disease (AD) was developed by scientists at the University Medical Center Göttingen. This antibody targets specifically only oligomeric Amyloid beta peptides.

Further Information: PDF

MBM ScienceBridge GmbH
Phone: (0551) 30724-151

Contact
Dr. Jens-Peter Horst

Comments (0)

Write a comment